A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
使用抗 IGF-1R 抗体西妥木单抗和 MEK 1/2 抑制剂司美替尼对晚期实体肿瘤进行 IGF 信号垂直抑制的 I 期临床试验
期刊:British Journal of Cancer
影响因子:6.4
doi:10.1038/bjc.2014.515
B A Wilky, M A Rudek, S Ahmed, D A Laheru, D Cosgrove, R C Donehower, B Nelkin, D Ball, L A Doyle, H Chen, X Ye, G Bigley, C Womack, N S Azad
